How India Exports Fosfomycin to the World

In the United States, fosfomycin is approved for the treatment of uncomplicated urinary tract infections. The FDA has approved several Abbreviated New Drug Applications (ANDAs) for generic versions of fosfomycin tromethamine. Notably, Alkem Laboratories Ltd. received approval on October 21, 2021, Amneal Pharmaceuticals on March 25, 2024, and Aurobindo Pharma Ltd. on November 14, 2025. These approvals have facilitated the entry of Indian exporters into the U.S. market, with Amneal Pharmaceuticals Private Limited contributing 1.7% to India's fosfomycin exports.

The regulatory pathway for fosfomycin in the U.S. involves demonstrating bioequivalence to the reference listed drug, Monurol. As of February 2026, all formulations of Monurol have been discontinued, yet generic versions remain available. There are no current import alerts or significant regulatory actions affecting fosfomycin imports from India, indicating a stable regulatory environment for Indian exporters.

In the European Union, fosfomycin is authorized for use in treating various bacterial infections. The European Medicines Agency (EMA) oversees the approval process, ensuring compliance with EU Good Manufacturing Practice (GMP) standards. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates the marketing authorization of fosfomycin, adhering to stringent GMP requirements. Indian exporters must meet these standards to access the EU and UK markets.

Fosfomycin is not included in the WHO Model List of Essential Medicines as of the 24th edition published in September 2025. However, it is recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different markets.

In India, fosfomycin is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for fosfomycin, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and international standards.

The primary patents for fosfomycin have expired, leading to increased generic competition. This has enabled multiple Indian pharmaceutical companies to manufacture and export fosfomycin, contributing to the diversification and growth of India's pharmaceutical export portfolio.

In March 2024, Amneal Pharmaceuticals received FDA approval for its generic version of fosfomycin tromethamine, enhancing the availability of this antibiotic in the U.S. market. Subsequently, in November 2025, Aurobindo Pharma Ltd. also secured FDA approval for its generic formulation, further intensifying competition among Indian exporters.

In January 2026, the WHO published the 24th edition of its Model List of Essential Medicines, which did not include fosfomycin. This exclusion may influence procurement decisions in certain markets, potentially affecting demand dynamics for Indian exporters.

Overall, the regulatory landscape for fosfomycin exported from India remains favorable, with established approvals in key markets and adherence to international quality standards. Indian exporters continue to play a pivotal role in supplying fosfomycin globally, leveraging their manufacturing capabilities and regulatory compliance.

Fosfomycin, an antibiotic used to treat bacterial infections, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, according to the U.S. Pharmacopeia's Medicine Supply Map.

Recent geopolitical tensions have exacerbated supply chain vulnerabilities. In February 2026, military escalations in the Middle East led to the effective shutdown of the Strait of Hormuz, a critical passage for global trade. This disruption has significantly impacted the supply of raw materials, including those essential for pharmaceutical manufacturing, leading to production cutbacks and force majeure declarations in the chemical industry.

Our proprietary trade data indicates a high concentration in Fosfomycin exports from India. The top five exporters account for 92.3% of the total export value, with CIPLA LIMITED alone contributing 74.5%. Such concentration poses a significant single-source risk, as any disruption affecting these key suppliers could severely impact global supply.

To mitigate this risk, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic production of critical APIs and reduce reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, marking a significant step towards self-sufficiency.

The closure of the Strait of Hormuz in March 2026 has disrupted global shipping routes, leading to increased freight rates and delays in the delivery of pharmaceutical products. This chokepoint handles a substantial portion of global trade, and its obstruction has ripple effects across various industries, including pharmaceuticals.

Additionally, the U.S. Food and Drug Administration (FDA) has been monitoring supply chain disruptions that could lead to drug shortages. While specific alerts for Fosfomycin have not been issued, the agency continues to assess the situation and collaborate with manufacturers to prevent potential shortages.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source.

• Enhance Domestic Production: Invest in local manufacturing capabilities for both APIs and KSMs to decrease reliance on imports.

• Strengthen Supply Chain Monitoring: Implement robust tracking systems to identify and address potential disruptions proactively.

• Develop Contingency Plans: Establish alternative logistics and shipping routes to mitigate the impact of geopolitical tensions.

• Collaborate with Regulatory Bodies: Work closely with agencies like the FDA to stay informed about potential shortages and regulatory changes.

RISK_LEVEL: HIGH